LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Center
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CDMO
      • Quality System
      • CDMO Service
      • Quality Control
      • Global CDMO
      • CDMO Inquiries
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • CDMO Inquiries
    • IR Inquiries

Mechanism of treatment for cartilage regeneration using stem cells, the first in the world

2013/06/23
STEM CELL THERAPEUTIC

MEDIPOST, will do research into the promotion of cartilage cell division by a specific protein…published in Stem Cell

A Korean group of researchers have found that a specific protein can promote the division of cartilage.

MEDIPOST has stated that the study on ‘The Mechanism of cartilage regeneration treatment using stem cells’ was published in one of the top journals in stem cell research, Stem Cell, on July 23.

MEDIPOST has produced results that the administration of mesenchymal stem cells extracted from the cord into the damaged knee joints of animals led to precursor cartilage cell division by various proteins, including TSAP-2, and published these results.

This study is meaningful in the era of various stem cell researches into cartilage regeneration treatment, because it has tested the hypothesis that ‘stem cells do not directly become cartilage cells, but rather, secrete specific proteins to induce cartilage production’.

The utilization of these results can lead to adjustment of the level of secretion of effective proteins within the stem cell treatment agent, or develop the optimal administration route and method, which can improve the success rate of cartilage regeneration treatment.

Stem Cell, which is where this study was published in, is one of the oldest and well known journals, with a SCI factor and IF of 7.701.

The related person from MEDIPOST said that ‘the publication of this study is to scientifically prove the mechanism of action of ‘CARTISTEM’ and have it recognized by the world’, and added, ‘this will hopefully lead to vitalization of cartilage-related research and the development of second generation CARTISTEM’.

VIEW LIST

Related News

MEDIPOST Recruits Local Experts to U.S. Subsidiary, Accelera…
2024/12/06
MEDIPOST Completes Administration for Phase 3 Clinical Trial…
2024/11/22
MEDIPOST Affiliate OmniaBio Hosts Opening Ceremony for New C…
2024/10/21
MEDIPOST Discusses CARTISTEM® Partnerships and Licensing Opp…
2024/10/14

Latest News

MEDIPOST Recruits Local Experts to U.S. Subsidiary, Accelera…
2024/12/06
MEDIPOST Completes Administration for Phase 3 Clinical Trial…
2024/11/22
MEDIPOST Affiliate OmniaBio Hosts Opening Ceremony for New C…
2024/10/21
MEDIPOST Discusses CARTISTEM® Partnerships and Licensing Opp…
2024/10/14
MEDIPOST’s CARTISTEM® Reaches Milestone of treating 30,000 P…
2024/06/24

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

Latest News

MEDIPOST Recruits Local Experts to U.S.…2024.12.06
MEDIPOST Completes Administration for Ph…2024.11.22
MEDIPOST Affiliate OmniaBio Hosts Openin…2024.10.21
MEDIPOST Discusses CARTISTEM® Partnershi…2024.10.14
MEDIPOST’s CARTISTEM® Reaches Milestone…2024.06.24

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST